- Home
- VTYX
as 11-04-2025 4:00pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Upcoming Earnings Alert:
Get ready for potential market movements as Ventyx Biosciences Inc. VTYX prepares to release earnings report on 06 Nov 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 154.9M | IPO Year: | 2021 |
| Target Price: | $12.50 | AVG Volume (30 days): | 9.8M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $9.50 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Ventyx Biosciences (VTYX): Assessing Valuation After Breakthrough Phase 2 Results for VTX3232
MT Newswires
12 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
12 days ago
Sector Update: Health Care
MT Newswires
12 days ago
Top Midday Gainers
Associated Press Finance
12 days ago
BC-Most Active Stocks
MT Newswires
12 days ago
Tesla Earnings Dent Investor Sentiment, Driving Narrow Premarket Losses for US Equity Futures
MT Newswires
13 days ago
Top Premarket Gainers
BioPharma Dive
13 days ago
Ventyx shares soar after study suggests cardiovascular benefits for experimental drug
Compare VTYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTYX Ventyx Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.